S. 1542 · 119th Congress · International Affairs

Uyghur Policy Act of 2026

Establishes policy regarding Uyghurs and related international affairs. AI-read

Out of committee4.4k words Introduced Apr 30, 2025 · Latest action Jul 27, 2026

How far it has goneStage 3 of 6
  1. IntroducedApr 30, 2025 Done
  2. CommitteeReported Jul 27, 2026 Done
  3. Senate floorAwaiting vote Current stage
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

The Congressional Research Service hasn’t published a summary of this bill. Read the full text on Congress.gov.

Who lobbies on it

5 organizations · 15 filings · Q2 2025–Q3 2026

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Pharmaceutical Research and Manufacturers of America 6 of 6 quarters
    “Pharmacy Benefit Manager (PBM) issues and reform. 340B. IRA implementation. H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act. Drug pricing. Most-Favored Nation (MFN) International reference pricing. H.R.5378 - Lower Costs, More Transparency Act. H.R.5376 - Share the Savings with Seniors Act. H.R.6283/S.1542…”

    Q3 2026 filing · $26.6M lobbying spend in 2026 to date, all issues

  2. Sanofi Us Services Inc 6 of 6 quarters
    “340B; Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Clinical Trial Data Requirements; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research…”

    Q3 2026 filing · $4.8M lobbying spend in 2026 to date, all issues

  3. Blue Cross Blue Shield of Michigan 1 of 6 quarters
    “Bills: S. 1114, Expanding Access to Low-Cost Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit…”

    Q2 2025 filing · $1.1M lobbying spend in 2025, all issues

2 more organizations, every filingPROUpgrade

Organizations that named S. 1542 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

5 actions · newest first
  1. Jul 27, 2026Placed on Senate Legislative Calendar under General Orders. Calendar No. 496.
  2. Jul 27, 2026Committee on Foreign Relations. Reported by Senator Risch with an amendment in the nature of a substitute. Without written report.
  3. Jun 17, 2026Committee on Foreign Relations. Ordered to be reported with an amendment in the nature of a substitute favorably.
  4. Apr 30, 2025Read twice and referred to the Committee on Foreign Relations.
Show all 5 actionsShow fewer
  1. Apr 30, 2025Introduced in Senate